Novartis said the biomarker cohort of its Phase 1/2 FORTITUDE trial for Del-brax met both primary and secondary endpoints in treating facioscapulohumeral muscular dystrophy (FSHD). The result is a positive clinical-development update for the drug candidate and supports progression of the program. Market impact is likely limited to Novartis and closely watched biotech peers rather than the broader market.
Novartis said the biomarker cohort of its Phase 1/2 FORTITUDE trial for Del-brax met both primary and secondary endpoints in treating facioscapulohumeral muscular dystrophy (FSHD). The result is a positive clinical-development update for the drug candidate and supports progression of the program. Market impact is likely limited to Novartis and closely watched biotech peers rather than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
